Manisha Singh, MD
Internal Medicine · Little Rock, ARNPI 1831410356
Payments from drug & device makers
What this record shows
5 manufacturers reported payments, led by Chiesi USA, Inc. at 40.0% of the total.
Across 10 payments — averaging $112.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Chiesi USA, Inc.$450
- Gilead$421
- Calliditas Therapeutics US Inc.$107
- Inari Medical, Inc.$96
- Novartis$50
Across 1 payment — averaging $70,250 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Baxter Healthcare$70K
What the payments were for
- Speaking & faculty fees$45040%
- Food & beverage$67460%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Chiesi USA, Inc. | 1 | $450 |
| Gilead | 6 | $421 |
| Calliditas Therapeutics US Inc. | 1 | $107 |
| Inari Medical, Inc. | 1 | $96 |
| Novartis | 1 | $50 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,124 in reported general payments places this provider in the 75th percentile of 614 internal medicine providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 11 | $16,070 |
| FarxigaDapagliflozin Propanediol | 16 | $14,032 |
| Sevelamer Carbonate | 22 | $2,016 |
| Paricalcitol | 12 | $1,518 |
| Nifedipine ErNifedipine | 40 | $1,414 |
| Calcitriol | 50 | $497 |
| Westab PlusPnv,calcium 72/Iron/Folic Acid | 16 | $343 |
| Chlorthalidone | 16 | $339 |
| Potassium Chloride | 27 | $307 |
| Allopurinol | 50 | $243 |
| Lisinopril | 20 | $226 |
| Lactulose | 13 | $209 |
| Torsemide | 11 | $206 |
| Minoxidil | 13 | $193 |
| Losartan Potassium | 15 | $165 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Little Rock
- Aaron StrobelLittle Rock$32K
- Jeremy DavisLittle Rock$17K
- Ritesh RampureLittle Rock$13K
- Milton RoachLittle Rock$12K
- Michael CloudLittle Rock$10K
- Saul Rios HerreraLittle Rock$8K
- Zhangning ChenLittle Rock$8K
- Russell RoarkLittle Rock$7K
- Arpana EdalaLittle Rock$6K
- Srikanth VallurupalliLittle Rock$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.